123 related articles for article (PubMed ID: 2172396)
1. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies.
Marshall GS; Ricciardi RP; Rando RF; Puck J; Ge RW; Plotkin SA; Gönczöl E
J Infect Dis; 1990 Nov; 162(5):1177-81. PubMed ID: 2172396
[TBL] [Abstract][Full Text] [Related]
2. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
[TBL] [Abstract][Full Text] [Related]
3. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity.
Gönczöl E; deTaisne C; Hirka G; Berencsi K; Lin WC; Paoletti E; Plotkin S
Vaccine; 1991 Sep; 9(9):631-7. PubMed ID: 1659051
[TBL] [Abstract][Full Text] [Related]
4. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.
Britt WJ; Vugler L; Butfiloski EJ; Stephens EB
J Virol; 1990 Mar; 64(3):1079-85. PubMed ID: 2154594
[TBL] [Abstract][Full Text] [Related]
5. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage.
Spaete RR; Thayer RM; Probert WS; Masiarz FR; Chamberlain SH; Rasmussen L; Merigan TC; Pachl C
Virology; 1988 Nov; 167(1):207-25. PubMed ID: 2460994
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections.
Genini E; Percivalle E; Sarasini A; Revello MG; Baldanti F; Gerna G
J Clin Virol; 2011 Oct; 52(2):113-8. PubMed ID: 21820353
[TBL] [Abstract][Full Text] [Related]
7. Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.
Ye X; Su H; Wrapp D; Freed DC; Li F; Yuan Z; Tang A; Li L; Ku Z; Xiong W; Jaijyan D; Zhu H; Wang D; McLellan JS; Zhang N; Fu TM; An Z
PLoS Pathog; 2020 Aug; 16(8):e1008736. PubMed ID: 32745149
[TBL] [Abstract][Full Text] [Related]
8. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB).
Britt WJ; Vugler L; Stephens EB
J Virol; 1988 Sep; 62(9):3309-18. PubMed ID: 2841483
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.
Marshall GS; Rabalais GP; Stout GG; Waldeyer SL
J Infect Dis; 1992 Feb; 165(2):381-4. PubMed ID: 1309850
[TBL] [Abstract][Full Text] [Related]
10. Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus (HCMV) infection.
Park JW; Kim DJ; Kim J; Park CG; Hwang ES; Cha CY
J Korean Med Sci; 2000 Apr; 15(2):133-8. PubMed ID: 10803687
[TBL] [Abstract][Full Text] [Related]
11. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.
Cranage MP; Kouzarides T; Bankier AT; Satchwell S; Weston K; Tomlinson P; Barrell B; Hart H; Bell SE; Minson AC
EMBO J; 1986 Nov; 5(11):3057-63. PubMed ID: 3024973
[TBL] [Abstract][Full Text] [Related]
12. Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells.
Wells DE; Vugler LG; Britt WJ
J Gen Virol; 1990 Apr; 71 ( Pt 4)():873-80. PubMed ID: 2157800
[TBL] [Abstract][Full Text] [Related]
13. Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells.
Marshall GS; Fenger DP; Stout GG; Knights ME; Hunt LA
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1549-57. PubMed ID: 8757998
[TBL] [Abstract][Full Text] [Related]
14. Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection.
Schleiss MR; Jensen NJ
J Virol Methods; 2003 Mar; 108(1):59-65. PubMed ID: 12565154
[TBL] [Abstract][Full Text] [Related]
15. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization.
Speckner A; Glykofrydes D; Ohlin M; Mach M
J Gen Virol; 1999 Aug; 80 ( Pt 8)():2183-2191. PubMed ID: 10466818
[TBL] [Abstract][Full Text] [Related]
16. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response.
Shimamura M; Mach M; Britt WJ
J Virol; 2006 May; 80(9):4591-600. PubMed ID: 16611919
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.
Gerna G; Percivalle E; Perez L; Lanzavecchia A; Lilleri D
J Virol; 2016 Jul; 90(14):6216-6223. PubMed ID: 27122579
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.
Navarro D; Lennette E; Tugizov S; Pereira L
J Med Virol; 1997 Aug; 52(4):451-9. PubMed ID: 9260696
[TBL] [Abstract][Full Text] [Related]
19. Towards a novel vaccine against human cytomegalovirus based on a chimeric Ad5F35 adenovirus vector expressing the immunodominant antigenic domain 1 epitope.
Zhao P; Ma D; Yan S; Shao N; Zhang J; Bi Z; Dai J; Ji M; Ji C
Intervirology; 2009; 52(1):35-42. PubMed ID: 19372702
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy.
Eggers M; Radsak K; Enders G; Reschke M
J Med Virol; 2001 Feb; 63(2):135-42. PubMed ID: 11170050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
